25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis

Bone

Volumn 51, Issue 1, 2012, Pages 54-58

  Peris, Pilar ^a   Martínez Ferrer, Angeles ^b   Monegal, Ana ^a   Martínez de Osaba, M Jesús ^c   Muxi, Africa ^d   Guañabens, Nuria ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Rheumatology Dpt   (Spain)

^c Hormone Laboratory   (Spain)

^d Dpt of Nuclear Medicine   (Spain)

Author keywords

25 hydroxyvitamin d; Adequate response; Bisphosphonates; Muscle strength; Osteoporosis; Vitamin d supplements

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; PARATHYROID HORMONE; RISEDRONIC ACID;

ADULT; AGED; ANAMNESIS; ARTICLE; BONE DENSITY; BONE FRAGILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG USE; FALLING; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MUSCLE STRENGTH; OSTEOLYSIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; URINE LEVEL; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; VITAMIN D;

EID: 84860299827     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.03.026     Document Type: Article

References (43)

1. Lips P., Hosking D., Lippuner K., Norquist J.M., Wehren L., Maalouf G., et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006, 260:245-254.
2. Mezquita-Raya P., Muñoz-Torres M., Luna J.D., Luna V., López-Rodríguez F., Torres-Vela E., et al. Relationship between vitamin D insufficiency, bone density and bone metabolism in healthy postmenopausal women. J Bone Miner Res 2001, 16:1408-1415.
3. Cerdá D., Peris P., Monegal A., Albaladejo C., Martínez M.A., Muxí A., et al. Search for hidden secondary causes in postemenopausal women with osteoporosis. Menopause 2010, 17:135-139.
4. Holick M.F. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
5. Gómez Alonso C., Naves Díaz M., Rodríguez García M., Fernández Martín J.L., Cannata Andía J.B. Review of the concept of vitamin D "sufficiency and insufficiency". Nefrologia 2003, 23:73-77.
6. Hanley D.A., Cranney A., Jones G., Whiting S.J., Leslie W.D., Cole D.E., et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010, 182:610-618.
7. Holick M.F., Siris E.S., Binkley N., Beard M.K., Khan A., Katzer J.T., et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005, 90:3215-3224.
8. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006, 116:2062-2072.
9. Díez-Pérez A., González-Macías J. Inadequate responders to osteoporosis treatment: proposal for an operacional definition. Osteoporos Int 2008, 19:1511-1516.
10. Adami S., Giannini S., Bianchi G., Sinigaglia S., Di Munno O., Fiorce C.E., et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009, 20:239-244.
11. Adami S., Isaia G., Luisetto G., Minusola S., Sinigaglia L., Gentilalla R., et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006, 21:1565-1570.
12. Orozco López P., Zwartz Salmeron M., Vilert Garrofa E.V., Olmos Domínguez C. Predicción de la ingesta total de calcio a través del consumo de lácteos en la población adulta de España. Estudio INDICAD 2001. Aten Primaria 2004, 33:237-243.
13. Morinsky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986, 24:67-74.
14. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
15. Dawson-Hughes B.N., Heaney R.P., Holick M.F., Lips P., Meunier P.J., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713-716.
16. Urbano-Marquez A., Estruch R., Navarro-Lopez F., Grau J.M., Mont L., Rubin E. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med 1989, 320:409-415.
17. Fernández-Solá J., Sacanella E., Estruch R., Nicolás J.M., Grau J.M., Urbano-Márquez A. Significance of type II fiber atrophy in chronic alcoholic myopathy. J Neurol Sci 1995, 130:69-76.
18. Adami S., Isaia G., Luisetto G., Minusola S., Sinigaglia L., Silvestri S., et al. Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 2008, 19:1219-1223.
19. Francis R.M. Non-response to osteoporosis treatment. J Br Menopause Soc 2004, 10:76-80.
20. Bonnick S., Broy S., Kaiser F., Teutsch C., Rosenberg E., DeLucca P., et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density. Curr Med Res Opin 2007, 23:1341-1349.
21. Antoniucci D.M., Vittinghoff E., Palermo L., Black D.M., Sellmeyer D.E. Vitamin D insufficiency does not affect response of bone mineral density to alendronate. Osteoporos Int 2009, 20:1259-1266.
22. Ishijima M., Sakamoto Y., Yamanaka M., Tokita A., Kitahara K., Kaneko H., et al. Minimun required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 2009, 85:398-404.
23. Barone A., Giusti A., Pioli G., Girasole G., Razzano M., Pizzonia M., et al. Secondary hyperparathyroidism due to hypovitaminosis D, affects bone mineral density response to alendronate in elderly women with osteoporosis. A randomized controlled trial. J Am Geriatr Soc 2007, 55:752-757.
24. Ross A.C., Manson J.E., Abrams S.A., Aloia J.F., Brannon P.M., Clinton S.K., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011, 96:53-58.
25. Carmel A., Shieh A., Bockman R. The 25(OH)D level associated with a favorable bisphosphonate response is >33ng/ml, J. J Bone Miner Res 2011, 26(Suppl. 1):S47. (Abstract).
26. Guardia G., Parikh N., Eskridge T., Phillips E., Divine G., Sundhaker Rao D. Prevalence of vitamin D depletion among subjects seeking advice on osteoporosis: a five-year cross-sectional study with public health implications. Osteoporos Int 2008, 19:13-19.
27. Crew K.D., Shane E., Cremers S., McMahon D.J., Irani D., Hershman D.L. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 2009, 27:2151-2156.
28. De Cock C., Bruyere O., Collette J., Reginster J.Y. Vitamin D inadequacy in French osteoporotic women. Joint Bone Spine 2008, 75:567-572.
29. Rosen C.J. Vitamin D insufficiency. N Engl J Med 2011, 364:248-254.
30. Stechschulte S.A., Kirsner R.S., Federman D.G. Vitamin D: bone and beyond, rationale and recommendations for supplementation. Am J Med 2009, 122:793-802.
31. Bischoff-Ferrari H. Vitamin D: what is an adequate vitamin D level and how much supplementation is necessary?. Best Pract Res Clin Rheumatol 2009, 23:789-795.
32. Bischoff-Ferrari H.A., Shao A., Dawson-Hughes B., Hathcock J., Giovannucci E., Willett W.C. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2010, 21:1121-1132.
33. Jackson R.D., LaCroix A.Z., Gass M., Wallace R.B., Robbins J., Lewis C.E. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006, 354:669-683.
34. Yendt E.R., Kovacs K.A., Glenville J. Secondary hyperparathyroidism in primary osteoporosis and osteopenia: optimising calcium and vitamin D intakes to levels recommended by expert panels may not be sufficient for correction. Clin Endocrinol 2008, 69:855-863.
35. Chen J.S., Sambrook P.N., March L., Cameron I.D., Cumming R.G., Simpson J.M., et al. Hypovitaminosis D and parathyroid hormone response in the elderly: effects on bone turnover and mortality. Clin Endocrinol 2008, 68:290-298.
36. Sørensen O.H., Lund B., Saltin B., Lund B., Andersen R.B., Hjorth L., et al. Myopathy in bone loss of ageing: improvement by treatment with 1 alpha-hydroxycholecalciferol and calcium. Clin Sci 1979, 56:157-161.
37. Pfeifer M., Begerow B., Minne H.W. Vitamin D and muscle function. Osteoporos Int 2002, 13:187-194.
38. Bischoff-Ferrari H.A., Dawson-Hughes B., Willett W.C., Staehelin H.B., Bazemore M.G., Zee R.Y., et al. Effect of vitamin D on falls: a meta-analysis. JAMA 2004, 291:1999-2006.
39. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992, 327:1637-1642.
40. Bouvard B., Annweiler C., Salle A., Beauchet O., Chappard D., Audran M., et al. Extraskeletal effects of vitamin D: facts, uncertainties, and controversies. Joint Bone Spine 2011, 78:10-16.
41. Annweiler C., Beauchet O., Berrut G., Fantino B., Bonnefoy M., Herrmann F.R., et al. Is there an association between serum 25-hydroxyvitamin D concentration and muscle strength among older women? Results from baseline assessment of EPIDOS study. J Nutr Health Aging 2009, 13:90-95.
42. Pramyothin P., Techasurungkul S., Lin J., Wang H., Shah A., Ross P.D., et al. Vitamin D status and falls, frailty, and fractures among postmenopausal Japanese women living in Hawaii. Osteoporos Int 2009, 20:1955-1962.
43. Glerup H., Mikkelsen K., Poulsen L., Hass E., Overbeck S., Andersen H., et al. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Int 2000, 66:419-424.